Lymphoma Flashcards
stage 1A hodgkins
2-4 cycles AVBD followed by IFRT; if low bulk <1/3 diameter or 10cm, then can give 2 cycles and 20Gy. if higher risk 4 Cycles and 30Gy
less favorable stage 1A HL
3+ sites, elevated ESR>50, bulk, B-symptoms: give 4 cycles AVBD and 30Gy radiation
brentuximab
anti-CD30, good for recurrent following auto
IPS HL risk factors for advanced disease
age>45, male, stage IV(visceral/BM+), albumin15, ALC<600(8%)
advanced HL high risk
consider escalated BEACOPP, but highly toxic
second line HL regimens
ICE followed by autoSCT
germinal cell type DLBCL
CD10+ BCL6+ MUM-1-
poor prognosis DLBCL
+BCL2+
low stage DLBCL
RCHOPx3–>RT unless risk of RT high, then can give RCHOP 4-6
HLPHL nodular lymphocyte predominant HL
hystiocytic cells, popcorn like–> express CD20, CD79a, CD30-, good survival despite relapses, –> can treat first with RT, relapse with more RT v. ritux v ABVD
CD20+CD5-CD10+CD23-
follicular lymphoma (CD10 positive–> most common)
CD103, CD123, CD11c, TRAP
Hairy cell markers
7q31 loss
splenic marginal zone
villous projections on lymphocyte
HCV v. splenic MZL
splenic MZL treatment
splenectomy; check for HCV as treatment of virus can result in remission
CD20+ CD5-CD10-CD23-
MZL (pan negative BCL)
t(11,18)
malt assocaited translocation- API2/MLT
t(11,18) MALT lymphoma
resistant to Abx therapy
t(14;18)
Bcl2 translocation
maintenance/consolidation
rituximab q2mo x 2 year, or consolidation RIT, improves PFS without OS
anaplastic large cell lymphoma
ALK translocation, CD30+ CD3+–> refractory treatment with brentuximab (can be CD3 negative)
t(2;5)
ALK:NPM–>ALCL
ALCL treatmetn
CHOP–>70% remission
t(11;14) or CD23+
mantle cell lymphoma; treatment is contentious, but alternating chemoimmunotherapy is common
MALT lymphoma H Pylori assocatied
treatment with antibiotic; localized can get radiotherapy;
SLL with 11q-
particular benefit for including of an alkylating agent–> FCR or PCR
